|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0001206,
umls-concept:C0019158,
umls-concept:C0030705,
umls-concept:C0087111,
umls-concept:C0205177,
umls-concept:C0205191,
umls-concept:C0205462,
umls-concept:C0205476,
umls-concept:C0282443,
umls-concept:C0438717,
umls-concept:C0456369,
umls-concept:C0547040,
umls-concept:C0596545,
umls-concept:C0684224,
umls-concept:C0700164,
umls-concept:C0733511,
umls-concept:C0913469,
umls-concept:C1552617,
umls-concept:C1556085
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2006-2-2
|
|
pubmed:abstractText |
The new GH receptor antagonist pegvisomant is the most effective medical therapy to normalize IGF-I levels in patients with acromegaly. Based on currently available data pegvisomant is well tolerated; however, treatment-induced elevation of transaminases has been reported and led to the necessity for drug discontinuation in some patients in the pivotal studies. The aim of this study was to evaluate and characterize the prevalence of elevated transaminases and to describe in detail the findings in a single case who required drug discontinuation because of elevation of transaminases which emerged during treatment and who underwent liver biopsy.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0804-4643
|
|
pubmed:author |
pubmed-author:BauditzJJ,
pubmed-author:BieringHH,
pubmed-author:BuchfelderMM,
pubmed-author:DrosteMM,
pubmed-author:German pegvisomant investigators,
pubmed-author:JohneAA,
pubmed-author:LochsHH,
pubmed-author:MannKK,
pubmed-author:PirlichMM,
pubmed-author:RudolphBB,
pubmed-author:SalleoAA,
pubmed-author:SchreiberII,
pubmed-author:StrasburgerC JCJ
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
154
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
213-20
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:16452533-Acromegaly,
pubmed-meshheading:16452533-Adult,
pubmed-meshheading:16452533-Alanine Transaminase,
pubmed-meshheading:16452533-Aspartate Aminotransferases,
pubmed-meshheading:16452533-Female,
pubmed-meshheading:16452533-Hepatitis, Chronic,
pubmed-meshheading:16452533-Histocytochemistry,
pubmed-meshheading:16452533-Human Growth Hormone,
pubmed-meshheading:16452533-Humans,
pubmed-meshheading:16452533-Insulin-Like Growth Factor I,
pubmed-meshheading:16452533-Male,
pubmed-meshheading:16452533-Receptors, Somatotropin,
pubmed-meshheading:16452533-Retrospective Studies
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Elevated transaminases during medical treatment of acromegaly: a review of the German pegvisomant surveillance experience and a report of a patient with histologically proven chronic mild active hepatitis.
|
|
pubmed:affiliation |
Department of Gastroenterology, Hepatology and Endocrinology, Charité-Universitätsmedizin Berlin, Germany.
|
|
pubmed:publicationType |
Journal Article,
Case Reports,
Research Support, Non-U.S. Gov't
|
